Mechanism

How it works

ACTH 1-39 binds primarily to the melanocortin-2 receptor (MC2R) on adrenal cortex cells, activating adenylyl cyclase via Gs-protein coupling, elevating cAMP, and triggering the steroidogenic cascade that converts cholesterol to cortisol and other glucocorticoids. It also binds MC1R, MC3R, MC4R, and MC5R on non-adrenal tissues, mediating anti-inflammatory, neuroprotective, and lipolytic effects independent of cortisol. The N-terminal 1-24 fragment contains the receptor-binding core, while residues 25-39 extend bioavailability and modulate receptor selectivity.

Reported in research

Benefits

Stimulates endogenous cortisol and adrenal steroid production for adrenal insufficiency testing and treatment
Exerts direct anti-inflammatory and immunomodulatory effects via peripheral melanocortin receptors
Neuroprotective and neurotrophic activity in the central nervous system, potentially supporting cognition and mood
Supports lipolysis and metabolic regulation through MC3R and MC4R signaling in adipose and hypothalamic tissues

Context, not a prescription

Dosing

Typical range: 250 mcg as a single diagnostic dose; therapeutic dosing varies widely (0.5–2 mg/day in some protocols) (Intramuscular, Subcutaneous)
Cycle length: Single dose for diagnostics; 2–8 weeks for therapeutic applications under medical supervision
Half-life: ~10–15 minutes (endogenous); depot formulations extend to hours

Safety

Side effects & contraindications

Possible side effects

Transient skin flushing and hyperpigmentation due to melanocortin receptor activation
Elevated cortisol leading to fluid retention, elevated blood pressure, and mood changes
Hypokalemia and electrolyte imbalances with prolonged use
Nausea, dizziness, or headache shortly after injection
Potential for adrenal suppression with chronic exogenous ACTH administration
Allergic or hypersensitivity reactions including anaphylaxis (rare)

Contraindications

Active systemic fungal infections (corticosteroid elevation may worsen infection)
Known hypersensitivity or allergy to ACTH or corticotropin preparations
Cushing's syndrome or other conditions of glucocorticoid excess
Uncontrolled hypertension
Scleroderma (risk of renal crisis with corticosteroid elevation)
Osteoporosis with high fracture risk

Research information, not medical advice. Always consult a licensed clinician before considering any peptide.

In depth

Full profile

What it does

You may notice increased energy and alertness from rising cortisol, possible skin flushing, and a sense of heightened stress resilience. Longer-term use may produce skin darkening (hyperpigmentation).

How it works

Think of ACTH 1-39 like a manager calling the warehouse (your adrenal glands) to ship out stress hormones. But this manager also walks around other departments — like the brain and immune system — giving direct instructions too.

After injection, ACTH 1-39 rapidly enters the bloodstream, binds to receptors on the adrenal glands within minutes, and triggers cortisol release. At the same time, it can bind to brain receptors that influence mood, memory, and alertness, and to immune cells that help regulate inflammation.

What to expect

Cortisol begins rising within 15–30 minutes of injection; peak cortisol levels typically occur at 30–60 minutes.

Week 1: Cortisol levels rise rapidly post-injection; you may feel more alert and energized, with some flushing or mild fluid retention.
Weeks 2-4: Anti-inflammatory effects become more noticeable; possible skin darkening from melanocortin activity; monitor for electrolyte changes and blood pressure.
Weeks 4-8: With continued use, adrenal glands may enlarge (hypertrophy); watch for signs of cortisol excess such as weight gain, mood swings, or sleep disruption.

Good to know

Never use without consulting a physician, as cortisol imbalance can have serious systemic effects
Start with the lowest effective dose and monitor blood pressure and electrolytes

Staying safe

Flushing or redness of the skin shortly after injection
Mild headache or dizziness
Increased appetite or fluid retention

Avoid if you have:

People with Cushing's syndrome or already-high cortisol levels
Those with active infections, especially fungal infections
People with uncontrolled high blood pressure

Overview

Acute: cortisol elevation (2–5x baseline), transient increase in aldosterone and DHEA, dose-dependent hyperpigmentation via MC1R-mediated melanogenesis, lipolytic activation in adipocytes via MC3/MC4R-cAMP-PKA-HSL pathway. Chronic: adrenocortical hypertrophy, sustained HPA axis sensitization, potential downregulation of MC2R with chronic supraphysiologic dosing, risk of iatrogenic Cushing's-like syndrome.

How it works

ACTH 1-39 functions like a master key that fits multiple locks distributed throughout the body. The primary lock (MC2R in the adrenal cortex) opens the vault releasing cortisol. But the same key also fits secondary locks in the brain (MC4R), immune cells (MC1R), and metabolic centers (MC3R), each releasing a different but coordinated physiological response — demonstrating pleiotropic ligand biology that cannot be replicated by downstream cortisol replacement alone.

Following IM or subQ administration, ACTH 1-39 has a very short plasma half-life (~10–15 minutes) due to rapid proteolytic degradation. Despite this, downstream cortisol elevations persist for 2–4 hours. Volume of distribution is low (~0.1 L/kg), suggesting limited tissue penetration beyond receptor-dense target organs. The full 1-39 sequence offers marginally improved receptor engagement at MC1R, MC3R, and MC4R compared to the 1-24 fragment, potentially amplifying extra-adrenal melanocortin effects. Chronic administration leads to adrenocortical hypertrophy and increased zona fasciculata and reticularis mass.

Onset & timeline

Peak plasma ACTH occurs within 5–10 minutes of IM injection. Adrenal cortisol secretion rises detectably within 15 minutes and peaks at 30–60 minutes post-dose. Central MC4R-mediated effects (appetite suppression, mood modulation) may manifest within 30–60 minutes, though CNS penetration is limited and primarily mediated by circumventricular organ access.

Days 1-3: Rapid cortisol elevation post-injection (15–60 min), peaking at ~30 min. Transient aldosterone rise may cause mild sodium retention. MC4R-mediated appetite modulation and mood shifts may be noticeable. Skin flushing from acute MC1R activation.
Weeks 1-2: Adrenocortical hypertrophy begins; cumulative hyperpigmentation increases with repeated dosing. HPA feedback dynamics shift — CRH and endogenous ACTH from the pituitary may suppress slightly. Anti-inflammatory effects via melanocortin pathway become measurable in inflammatory biomarkers (CRP, IL-6).
Weeks 2-8: Persistent glucocorticoid elevation begins manifesting systemically: potential glucose dysregulation, bone turnover changes, skin thinning, and immune modulation. MC2R downregulation may reduce adrenal responsiveness to further dosing. Monitor for features of Cushing's syndrome (central adiposity, striae, myopathy). Post-cycle HPA recovery may take 4–8 weeks.

Getting the most from it

Monitor serum cortisol, ACTH, electrolytes (Na+, K+), fasting glucose, and blood pressure at baseline and throughout any therapeutic course
Implement a structured taper protocol for cycles exceeding 4 weeks to allow HPA axis recovery and prevent adrenal insufficiency
Use the lowest efficacious dose; consider pulsatile rather than continuous dosing to minimize adrenocortical downregulation of MC2R
Baseline DEXA scan for bone density is prudent in therapeutic protocols exceeding 6 weeks

Common side effects

Hyperpigmentation of skin and mucous membranes secondary to melanocortin receptor activation — dose-dependent and partially reversible
Hypokalemia from aldosterone excess, particularly with high or prolonged doses — monitor serum electrolytes
Cortisol-mediated hyperglycemia and insulin resistance — relevant in diabetic or pre-diabetic patients
Hypertension from mineralocorticoid and glucocorticoid excess

Mechanism of action

ACTH 1-39 exerts its primary action through high-affinity binding to the melanocortin-2 receptor (MC2R, Kd ~1 nM), which is expressed exclusively in the adrenal cortex. MC2R couples to Gαs, activating adenylyl cyclase and elevating intracellular cAMP, which activates PKA. PKA phosphorylates steroidogenic acute regulatory protein (StAR), facilitating cholesterol transport into the mitochondrial inner membrane — the rate-limiting step in steroidogenesis — and upregulates CYP11A1 (cholesterol side-chain cleavage enzyme). This cascade drives production of cortisol, aldosterone, DHEA, and androstenedione. Separately, ACTH 1-39 engages MC1R on melanocytes and immune cells, MC3R/MC4R in the hypothalamus and limbic system (modulating appetite, mood, and neuroplasticity), and MC5R in exocrine glands. These extra-adrenal effects are independent of cortisol and include direct anti-inflammatory cytokine modulation (suppressing TNF-α, IL-1β, IL-6), pro-melanogenic signaling, and neuroprotection via CREB-mediated BDNF upregulation.

Following IM or subQ administration, ACTH 1-39 has a very short plasma half-life (~10–15 minutes) due to rapid proteolytic degradation. Despite this, downstream cortisol elevations persist for 2–4 hours. Volume of distribution is low (~0.1 L/kg), suggesting limited tissue penetration beyond receptor-dense target organs. The full 1-39 sequence offers marginally improved receptor engagement at MC1R, MC3R, and MC4R compared to the 1-24 fragment, potentially amplifying extra-adrenal melanocortin effects. Chronic administration leads to adrenocortical hypertrophy and increased zona fasciculata and reticularis mass.

Pharmacodynamics

Peak plasma ACTH occurs within 5–10 minutes of IM injection. Adrenal cortisol secretion rises detectably within 15 minutes and peaks at 30–60 minutes post-dose. Central MC4R-mediated effects (appetite suppression, mood modulation) may manifest within 30–60 minutes, though CNS penetration is limited and primarily mediated by circumventricular organ access.

Acute: cortisol elevation (2–5x baseline), transient increase in aldosterone and DHEA, dose-dependent hyperpigmentation via MC1R-mediated melanogenesis, lipolytic activation in adipocytes via MC3/MC4R-cAMP-PKA-HSL pathway. Chronic: adrenocortical hypertrophy, sustained HPA axis sensitization, potential downregulation of MC2R with chronic supraphysiologic dosing, risk of iatrogenic Cushing's-like syndrome.

Timeline

Days 1-3: Rapid cortisol elevation post-injection (15–60 min), peaking at ~30 min. Transient aldosterone rise may cause mild sodium retention. MC4R-mediated appetite modulation and mood shifts may be noticeable. Skin flushing from acute MC1R activation.
Weeks 1-2: Adrenocortical hypertrophy begins; cumulative hyperpigmentation increases with repeated dosing. HPA feedback dynamics shift — CRH and endogenous ACTH from the pituitary may suppress slightly. Anti-inflammatory effects via melanocortin pathway become measurable in inflammatory biomarkers (CRP, IL-6).
Weeks 2-8: Persistent glucocorticoid elevation begins manifesting systemically: potential glucose dysregulation, bone turnover changes, skin thinning, and immune modulation. MC2R downregulation may reduce adrenal responsiveness to further dosing. Monitor for features of Cushing's syndrome (central adiposity, striae, myopathy). Post-cycle HPA recovery may take 4–8 weeks.

Comparisons

ACTH 1-39 — effectiveness Very High, safety Moderate, cost $$, Medium to use
ACTH 1-24 (Cosyntropin) — effectiveness High, safety Good, cost $$, Medium to use
Semax (ACTH 4-10 analog) — effectiveness Moderate, safety Good, cost $, Low to use

Adverse effects

Common:

Hyperpigmentation of skin and mucous membranes secondary to melanocortin receptor activation — dose-dependent and partially reversible
Hypokalemia from aldosterone excess, particularly with high or prolonged doses — monitor serum electrolytes
Cortisol-mediated hyperglycemia and insulin resistance — relevant in diabetic or pre-diabetic patients
Hypertension from mineralocorticoid and glucocorticoid excess

Rare:

Anaphylaxis and severe hypersensitivity reactions — estimated incidence <0.1% but potentially life-threatening; epinephrine should be available
Adrenal crisis upon abrupt discontinuation after prolonged use due to HPA axis suppression

Contraindications & risk mitigation

Contraindicated in:

Patients with primary adrenocortical hyperfunction (Cushing's syndrome, adrenal adenoma)
Active or latent tuberculosis — glucocorticoid elevation can reactivate mycobacterial infections
Patients on CYP3A4-sensitive medications with narrow therapeutic index, as cortisol elevations can alter drug metabolism
Scleroderma — risk of normotensive renal crisis mediated by glucocorticoid excess
Patients with osteopenia/osteoporosis — chronic glucocorticoid elevation accelerates bone resorption

Monitor serum cortisol, ACTH, electrolytes (Na+, K+), fasting glucose, and blood pressure at baseline and throughout any therapeutic course
Implement a structured taper protocol for cycles exceeding 4 weeks to allow HPA axis recovery and prevent adrenal insufficiency
Use the lowest efficacious dose; consider pulsatile rather than continuous dosing to minimize adrenocortical downregulation of MC2R
Baseline DEXA scan for bone density is prudent in therapeutic protocols exceeding 6 weeks

Qué hace

You may notice increased energy and alertness from rising cortisol, possible skin flushing, and a sense of heightened stress resilience. Longer-term use may produce skin darkening (hyperpigmentation).

Cómo funciona

Think of ACTH 1-39 like a manager calling the warehouse (your adrenal glands) to ship out stress hormones. But this manager also walks around other departments — like the brain and immune system — giving direct instructions too.

After injection, ACTH 1-39 rapidly enters the bloodstream, binds to receptors on the adrenal glands within minutes, and triggers cortisol release. At the same time, it can bind to brain receptors that influence mood, memory, and alertness, and to immune cells that help regulate inflammation.

Qué esperar

Cortisol begins rising within 15–30 minutes of injection; peak cortisol levels typically occur at 30–60 minutes.

Week 1: Cortisol levels rise rapidly post-injection; you may feel more alert and energized, with some flushing or mild fluid retention.
Weeks 2-4: Anti-inflammatory effects become more noticeable; possible skin darkening from melanocortin activity; monitor for electrolyte changes and blood pressure.
Weeks 4-8: With continued use, adrenal glands may enlarge (hypertrophy); watch for signs of cortisol excess such as weight gain, mood swings, or sleep disruption.

Bueno saber

Never use without consulting a physician, as cortisol imbalance can have serious systemic effects
Start with the lowest effective dose and monitor blood pressure and electrolytes

Manteniéndose seguro

Flushing or redness of the skin shortly after injection
Mild headache or dizziness
Increased appetite or fluid retention

Evitar si tienes:

People with Cushing's syndrome or already-high cortisol levels
Those with active infections, especially fungal infections
People with uncontrolled high blood pressure

Descripción general

Acute: cortisol elevation (2–5x baseline), transient increase in aldosterone and DHEA, dose-dependent hyperpigmentation via MC1R-mediated melanogenesis, lipolytic activation in adipocytes via MC3/MC4R-cAMP-PKA-HSL pathway. Chronic: adrenocortical hypertrophy, sustained HPA axis sensitization, potential downregulation of MC2R with chronic supraphysiologic dosing, risk of iatrogenic Cushing's-like syndrome.

Cómo funciona

ACTH 1-39 functions like a master key that fits multiple locks distributed throughout the body. The primary lock (MC2R in the adrenal cortex) opens the vault releasing cortisol. But the same key also fits secondary locks in the brain (MC4R), immune cells (MC1R), and metabolic centers (MC3R), each releasing a different but coordinated physiological response — demonstrating pleiotropic ligand biology that cannot be replicated by downstream cortisol replacement alone.

Following IM or subQ administration, ACTH 1-39 has a very short plasma half-life (~10–15 minutes) due to rapid proteolytic degradation. Despite this, downstream cortisol elevations persist for 2–4 hours. Volume of distribution is low (~0.1 L/kg), suggesting limited tissue penetration beyond receptor-dense target organs. The full 1-39 sequence offers marginally improved receptor engagement at MC1R, MC3R, and MC4R compared to the 1-24 fragment, potentially amplifying extra-adrenal melanocortin effects. Chronic administration leads to adrenocortical hypertrophy and increased zona fasciculata and reticularis mass.

Inicio y cronología

Peak plasma ACTH occurs within 5–10 minutes of IM injection. Adrenal cortisol secretion rises detectably within 15 minutes and peaks at 30–60 minutes post-dose. Central MC4R-mediated effects (appetite suppression, mood modulation) may manifest within 30–60 minutes, though CNS penetration is limited and primarily mediated by circumventricular organ access.

Days 1-3: Rapid cortisol elevation post-injection (15–60 min), peaking at ~30 min. Transient aldosterone rise may cause mild sodium retention. MC4R-mediated appetite modulation and mood shifts may be noticeable. Skin flushing from acute MC1R activation.
Weeks 1-2: Adrenocortical hypertrophy begins; cumulative hyperpigmentation increases with repeated dosing. HPA feedback dynamics shift — CRH and endogenous ACTH from the pituitary may suppress slightly. Anti-inflammatory effects via melanocortin pathway become measurable in inflammatory biomarkers (CRP, IL-6).
Weeks 2-8: Persistent glucocorticoid elevation begins manifesting systemically: potential glucose dysregulation, bone turnover changes, skin thinning, and immune modulation. MC2R downregulation may reduce adrenal responsiveness to further dosing. Monitor for features of Cushing's syndrome (central adiposity, striae, myopathy). Post-cycle HPA recovery may take 4–8 weeks.

Cómo aprovecharlo al máximo

Monitor serum cortisol, ACTH, electrolytes (Na+, K+), fasting glucose, and blood pressure at baseline and throughout any therapeutic course
Implement a structured taper protocol for cycles exceeding 4 weeks to allow HPA axis recovery and prevent adrenal insufficiency
Use the lowest efficacious dose; consider pulsatile rather than continuous dosing to minimize adrenocortical downregulation of MC2R
Baseline DEXA scan for bone density is prudent in therapeutic protocols exceeding 6 weeks

Efectos secundarios comunes

Hyperpigmentation of skin and mucous membranes secondary to melanocortin receptor activation — dose-dependent and partially reversible
Hypokalemia from aldosterone excess, particularly with high or prolonged doses — monitor serum electrolytes
Cortisol-mediated hyperglycemia and insulin resistance — relevant in diabetic or pre-diabetic patients
Hypertension from mineralocorticoid and glucocorticoid excess

Mecanismo de acción

ACTH 1-39 exerts its primary action through high-affinity binding to the melanocortin-2 receptor (MC2R, Kd ~1 nM), which is expressed exclusively in the adrenal cortex. MC2R couples to Gαs, activating adenylyl cyclase and elevating intracellular cAMP, which activates PKA. PKA phosphorylates steroidogenic acute regulatory protein (StAR), facilitating cholesterol transport into the mitochondrial inner membrane — the rate-limiting step in steroidogenesis — and upregulates CYP11A1 (cholesterol side-chain cleavage enzyme). This cascade drives production of cortisol, aldosterone, DHEA, and androstenedione. Separately, ACTH 1-39 engages MC1R on melanocytes and immune cells, MC3R/MC4R in the hypothalamus and limbic system (modulating appetite, mood, and neuroplasticity), and MC5R in exocrine glands. These extra-adrenal effects are independent of cortisol and include direct anti-inflammatory cytokine modulation (suppressing TNF-α, IL-1β, IL-6), pro-melanogenic signaling, and neuroprotection via CREB-mediated BDNF upregulation.

Following IM or subQ administration, ACTH 1-39 has a very short plasma half-life (~10–15 minutes) due to rapid proteolytic degradation. Despite this, downstream cortisol elevations persist for 2–4 hours. Volume of distribution is low (~0.1 L/kg), suggesting limited tissue penetration beyond receptor-dense target organs. The full 1-39 sequence offers marginally improved receptor engagement at MC1R, MC3R, and MC4R compared to the 1-24 fragment, potentially amplifying extra-adrenal melanocortin effects. Chronic administration leads to adrenocortical hypertrophy and increased zona fasciculata and reticularis mass.

Farmacodinamia

Peak plasma ACTH occurs within 5–10 minutes of IM injection. Adrenal cortisol secretion rises detectably within 15 minutes and peaks at 30–60 minutes post-dose. Central MC4R-mediated effects (appetite suppression, mood modulation) may manifest within 30–60 minutes, though CNS penetration is limited and primarily mediated by circumventricular organ access.

Acute: cortisol elevation (2–5x baseline), transient increase in aldosterone and DHEA, dose-dependent hyperpigmentation via MC1R-mediated melanogenesis, lipolytic activation in adipocytes via MC3/MC4R-cAMP-PKA-HSL pathway. Chronic: adrenocortical hypertrophy, sustained HPA axis sensitization, potential downregulation of MC2R with chronic supraphysiologic dosing, risk of iatrogenic Cushing's-like syndrome.

Cronología

Days 1-3: Rapid cortisol elevation post-injection (15–60 min), peaking at ~30 min. Transient aldosterone rise may cause mild sodium retention. MC4R-mediated appetite modulation and mood shifts may be noticeable. Skin flushing from acute MC1R activation.
Weeks 1-2: Adrenocortical hypertrophy begins; cumulative hyperpigmentation increases with repeated dosing. HPA feedback dynamics shift — CRH and endogenous ACTH from the pituitary may suppress slightly. Anti-inflammatory effects via melanocortin pathway become measurable in inflammatory biomarkers (CRP, IL-6).
Weeks 2-8: Persistent glucocorticoid elevation begins manifesting systemically: potential glucose dysregulation, bone turnover changes, skin thinning, and immune modulation. MC2R downregulation may reduce adrenal responsiveness to further dosing. Monitor for features of Cushing's syndrome (central adiposity, striae, myopathy). Post-cycle HPA recovery may take 4–8 weeks.

Comparaciones

ACTH 1-39 — efectividad Very High, seguridad Moderate, costo $$, Medium de usar
ACTH 1-24 (Cosyntropin) — efectividad High, seguridad Good, costo $$, Medium de usar
Semax (ACTH 4-10 analog) — efectividad Moderate, seguridad Good, costo $, Low de usar

Efectos adversos

Comunes:

Hyperpigmentation of skin and mucous membranes secondary to melanocortin receptor activation — dose-dependent and partially reversible
Hypokalemia from aldosterone excess, particularly with high or prolonged doses — monitor serum electrolytes
Cortisol-mediated hyperglycemia and insulin resistance — relevant in diabetic or pre-diabetic patients
Hypertension from mineralocorticoid and glucocorticoid excess

Raros:

Anaphylaxis and severe hypersensitivity reactions — estimated incidence <0.1% but potentially life-threatening; epinephrine should be available
Adrenal crisis upon abrupt discontinuation after prolonged use due to HPA axis suppression

Contraindicaciones y mitigación de riesgos

Contraindicado en:

Patients with primary adrenocortical hyperfunction (Cushing's syndrome, adrenal adenoma)
Active or latent tuberculosis — glucocorticoid elevation can reactivate mycobacterial infections
Patients on CYP3A4-sensitive medications with narrow therapeutic index, as cortisol elevations can alter drug metabolism
Scleroderma — risk of normotensive renal crisis mediated by glucocorticoid excess
Patients with osteopenia/osteoporosis — chronic glucocorticoid elevation accelerates bone resorption

Monitor serum cortisol, ACTH, electrolytes (Na+, K+), fasting glucose, and blood pressure at baseline and throughout any therapeutic course
Implement a structured taper protocol for cycles exceeding 4 weeks to allow HPA axis recovery and prevent adrenal insufficiency
Use the lowest efficacious dose; consider pulsatile rather than continuous dosing to minimize adrenocortical downregulation of MC2R
Baseline DEXA scan for bone density is prudent in therapeutic protocols exceeding 6 weeks

Reference data

Specifications

Molecular formula: C207H308N56O58S
Molecular weight: 4541.1 Da
Half-life: ~10–15 minutes (endogenous); depot formulations extend to hours
Route: Intramuscular, Subcutaneous
Cycle length: Single dose for diagnostics; 2–8 weeks for therapeutic applications under medical supervision
Storage: Lyophilized powder: store at 2–8°C (refrigerated), protect from light and moisture. Once reconstituted, use within 24 hours if stored at 2–8°C. Do not freeze reconstituted solution.
Legal status: Prescription-only medication in most jurisdictions (FDA-approved as Cortrosyn/cosyntropin for diagnostic use); research-grade peptide available without prescription in some countries for investigational purposes only.

FAQ

Common questions

How does ACTH 1-39 differ mechanistically from ACTH 1-24 (cosyntropin)?

Both fragments fully activate MC2R on the adrenal cortex — the 1-24 N-terminal sequence contains the entire adrenal-stimulating domain. ACTH 1-39 additionally provides the C-terminal 25-39 extension, which may enhance binding to MC1R, MC3R, and MC4R, potentially amplifying extra-adrenal melanocortin effects including neuroprotection and direct immunomodulation. However, the clinical significance of the additional receptor engagement from the full 1-39 sequence versus 1-24 has not been rigorously quantified in head-to-head human trials.

Can ACTH 1-39 be used to restore adrenal function after prolonged corticosteroid use?

There is some theoretical rationale for using low-dose ACTH to rehabilitate a suppressed HPA axis by directly stimulating adrenocortical cells. However, the standard clinical approach remains a gradual corticosteroid taper. Exogenous ACTH itself can paradoxically maintain adrenocortical suppression of endogenous CRH/ACTH if used at supraphysiologic doses. This application requires careful endocrinological supervision.

What is the evidence for ACTH's direct neuroprotective effects independent of cortisol?

Preclinical studies in rodents demonstrate ACTH fragment-mediated neuroprotection, improved learning and memory via MC4R/CREB/BDNF pathways, and anti-apoptotic effects in hippocampal neurons. Limited human data exist; most central nervous system applications remain in the preclinical or early-stage investigational phase. ACTH(4-9) analog Semax has been developed specifically to target CNS melanocortin receptors without adrenal stimulation.

What is the evidence level?

This compound is classified as Clinical evidence. Randomized controlled trial data in humans exists and supports use in specific contexts.

Research

Research & sources

Clinical evidence

Current evidence for ACTH 1-39 is rated as Clinical evidence. Human clinical evidence supports the reported effects.

1. Structure and function of adrenocorticotropin (2003) — Endocrine Reviews 24(3):374-402
2. Melanocortin receptors: their ligands, physiological functions and the effects of their deficiency (2006) — Pharmacological Reviews 58(2):261-284
3. ACTH and the adrenocortical axis: basic science and clinical aspects (2016) — Clinical Endocrinology 84(1):1-12
4. Extra-adrenal effects of ACTH on immune and nervous system function (2011) — Annals of the New York Academy of Sciences 1220:139-148

Explore

Often discussed alongside

BPC-157 · healing TB-500 · healing Selank · cognition PT-141 (Bremelanotide) · sexual